This study can be used to do both, notes Dr
You may be wondering why we prioritize Tirzepatide in 2026
LevyJRodriguez-GueantR-MOussalahAJeannessonEWahlDZiulySet al
In another report, a 26week treatment with the GLP1R/GIPR dual agonist LY3298176 (Tirzepatide, Eli Lilly), showed significant reduction in A1c in an incremental, dosedependent manner (4 doses from 1 mg to 15 mg, A1c reduction from 1.06% to 1.94% respectively)
Incorporate Physical Activity Regular physical activity complements the effects of GLP-1 medications
The dose-dependent effect of GLP-1 on decelerating gastric emptying plays a substantial role in improving postprandial glycemic concentrations to the extent that postprandial insulin secretion may no longer be stimulated or could even be reduced (154, 155) ( Figure 1 Section D)